Lupin has informed that it enclosed a Press Release as regards, the successful completion of GMP Inspection by the U.S. FDA, of the Company’s API manufacturing facility located at Dabhasa, India. The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations.
The above information is a part of company’s filings submitted to BSE.